Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with ...

Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and ...

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma.

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors ...

The field of Cancer Immunity & Immunotherapy is entering an exciting new phase. While Volume I (see here) of this Research Topic highlighted broad ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.